Evidence map›Paper›PMID 36670405›Full record

ArticleBMC cancer2023

Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy.

Tetsunori Sakamoto, Masahiko Ajiro, Akira Watanabe, Shingo Matsushima, Keiji Ueda, Masatoshi Hagiwara

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. TRMT6-Mediated mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tetsunori SakamotoDepartment of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Building C, 3Rd Floor, Yoshida-Konoe Cho, Sakyo-Ku, Kyoto, 606-8501, Japan.
Masahiko AjiroDepartment of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Building C, 3Rd Floor, Yoshida-Konoe Cho, Sakyo-Ku, Kyoto, 606-8501, Japan. ajiro.masahiko.6e@kyoto-u.ac.jp.
Akira WatanabeMedical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, 606-8397, Japan.
Shingo MatsushimaDepartment of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan.
Keiji UedaDivision of Virology, Osaka University Graduate School of Medicine, Suita, 565-0871, Japan.
Masatoshi HagiwaraDepartment of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Building C, 3Rd Floor, Yoshida-Konoe Cho, Sakyo-Ku, Kyoto, 606-8501, Japan. hagiwara.masatoshi.8c@kyoto-u.ac.jp.
Kyoto University · JPOsaka University · JPOtsu Red Cross Hospital · JP

Funding

the Japan Society for the Promotion of Science 15H05721
6 · The paper itself

Abstract

Chronic infection with Kaposi's sarcoma-associated herpes virus (KSHV) in B lymphocytes causes primary effusion lymphoma (PEL), the most aggressive form of KSHV-related cancer, which is resistant to conventional chemotherapy. In this study, we report that the BCBL-1 KSHV

Indexed as

Herpesvirus 8, HumanLymphoma, Primary EffusionNeoplasmsSarcoma, KaposiCyclin-Dependent Kinase 9HumansPyridinesCDK9 protein, humanCyclin-Dependent Kinase 9FIT-039PyridinesBCBL-1 xenograftCyclin-dependent kinase 9FIT-039Kaposi’s sarcoma-associated herpesvirusPrimary effusion lymphoma

Identifiers

PMID36670405
PMCPMC9862866
OpenAlexW4317566112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.